Diaceutics PLC Block Listing Application to AIM (4207O)
October 02 2023 - 10:59AM
UK Regulatory
TIDMDXRX
RNS Number : 4207O
Diaceutics PLC
02 October 2023
Block Listing Application to AIM
Belfast and London, 2 October 2023 - Diaceutics PLC (AIM: DXRX)
, a leading technology and solutions provider to the pharmaceutical
industry, today announces an application has been made to AIM for a
block listing of 1,500,000 ordinary shares of GBP0.002 each in the
Company ("Ordinary Shares"). This will be used to facilitate the
admission of shares to trading following the exercise of options
granted under the following Company's share schemes:
-- the UK and Global Share Incentive Plan for employees
(the "SIP"); and
-- the Employee Share Option Plan (the "ESOP") which includes
long term incentive awards.
The Ordinary Shares will be issued from time to time pursuant to
the Company's existing plans including outstanding options already
issued but not yet exercised to the employees of the Company. New
Ordinary Shares issued following option exercises and admitted to
trading under the block admission will rank pari passu in all
respects with the existing Ordinary Shares.
The block listing is expected to become effective on or around 6
October 2023. The Company will make six-monthly announcements of
the utilisation of the block admission, in line with its obligation
under AIM Rule 29.
At the time of this announcement, Diaceutics has 84,472,431
Ordinary Shares in issue. This figure may be used by shareholders
in the Company as a denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
For further information from Diaceutics PLC, please contact:
Enquiries:
Diaceutics PLC Tel: +44 (0)28 9040 6500
Nick Roberts, Chief Financial Officer investorrelations@diaceutics.com
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0)20 7710 7600
& Broker)
Ben Maddison
Nick Harland
Kate Hanshaw
Alma Tel: +44(0)20 3405 0205
Caroline Forde diaceutics@almapr.co.uk
Matthew Young
Kinvara Verdon
About Diaceutics
At Diaceutics we believe that every patient should get the
opportunity to receive the right test and the right therapy to
positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with
an end-to-end commercialisation solution for precision medicines
through data analytics, scientific and advisory services enabled by
our platform DXRX - The Diagnostics Network (R)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBSBDGDUGDGXD
(END) Dow Jones Newswires
October 02, 2023 10:59 ET (14:59 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2024 to Jun 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Jun 2023 to Jun 2024